Form 6-K Polyrizon Ltd. For: May 04

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of May 2026

 

Commission file number: 001-42375

 

Polyrizon Ltd.

(Translation of registrant’s name into English)

 

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

CONTENTS

        

Attached hereto and incorporated herein is the Registrant’s press release issued on May 4, 2026, titled “Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform.”

 

 

EXHIBIT INDEX

 

Exhibit No.
99.1		Press release titled: “Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Polyrizon Ltd.
Date: May 4, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES U.S. PATENT EXPANSION FOR ITS INTRANASAL DRUG DELIVERY PLATFORM"

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bekaert: Update on the Share Buyback Program and the Liquidity Agreement
• Next Crypto To Explode: AlphaPepe’s $0.0218 Entry Fuels the $1 Roadmap Debate Before Public Trading
• Galantas Announces Amendment to a Dragones Share Purchase Agreement